1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Contact Lenses Overview

3 Products under Development
3.1 Contact Lenses - Pipeline Products by Stage of Development
3.2 Contact Lenses - Pipeline Products by Segment
3.3 Contact Lenses - Pipeline Products by Territory
3.4 Contact Lenses - Pipeline Products by Regulatory Path
3.5 Contact Lenses - Pipeline Products by Estimated Approval Date
3.6 Contact Lenses - Ongoing Clinical Trials

4 Contact Lenses - Pipeline Products under Development by Companies
4.1 Contact Lenses Companies - Pipeline Products by Stage of Development
4.2 Contact Lenses - Pipeline Products by Stage of Development

5 Contact Lenses Companies and Product Overview
5.1 Aeon Astron Corporation Company Overview
5.1.1 Aeon Astron Corporation Pipeline Products & Ongoing Clinical Trials Overview
5.2 Ai Kangte Medical Technology Co Ltd Company Overview
5.2.1 Ai Kangte Medical Technology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.3 Alcon Inc Company Overview
5.3.1 Alcon Inc Pipeline Products & Ongoing Clinical Trials Overview
5.4 Apeliotus Ophthalmics (Ictive) Company Overview
5.4.1 Apeliotus Ophthalmics (Ictive) Pipeline Products & Ongoing Clinical Trials Overview
5.5 Axcelon Biopolymers Corp. Company Overview
5.5.1 Axcelon Biopolymers Corp. Pipeline Products & Ongoing Clinical Trials Overview
5.6 Azalea Vision Company Overview
5.6.1 Azalea Vision Pipeline Products & Ongoing Clinical Trials Overview
5.7 Bar-Ilan University Company Overview
5.7.1 Bar-Ilan University Pipeline Products & Ongoing Clinical Trials Overview
5.8 Bausch & Lomb Inc Company Overview
5.8.1 Bausch & Lomb Inc Pipeline Products & Ongoing Clinical Trials Overview
5.9 Bionode LLC Company Overview
5.9.1 Bionode LLC Pipeline Products & Ongoing Clinical Trials Overview
5.10 Clerio Vision Inc Company Overview
5.10.1 Clerio Vision Inc Pipeline Products & Ongoing Clinical Trials Overview
5.11 CooperVision Inc Company Overview
5.11.1 CooperVision Inc Pipeline Products & Ongoing Clinical Trials Overview
5.12 Euclid Systems Corp Company Overview
5.12.1 Euclid Systems Corp Pipeline Products & Ongoing Clinical Trials Overview
5.13 e-Vision Medical Devices, Inc. Company Overview
5.13.1 e-Vision Medical Devices, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.14 Eyenovations Company Overview
5.14.1 Eyenovations Pipeline Products & Ongoing Clinical Trials Overview
5.15 EyeYon Medical Company Overview
5.15.1 EyeYon Medical Pipeline Products & Ongoing Clinical Trials Overview
5.16 Imperial College London Company Overview
5.16.1 Imperial College London Pipeline Products & Ongoing Clinical Trials Overview
5.17 Industrial Science & Technology Network Inc Company Overview
5.17.1 Industrial Science & Technology Network Inc Pipeline Products & Ongoing Clinical Trials Overview
5.18 Innovega Inc Company Overview
5.18.1 Innovega Inc Pipeline Products & Ongoing Clinical Trials Overview
5.19 Johnson & Johnson Vision Care Inc Company Overview
5.19.1 Johnson & Johnson Vision Care Inc Pipeline Products & Ongoing Clinical Trials Overview
5.20 Kubota Vision Inc Company Overview
5.20.1 Kubota Vision Inc Pipeline Products & Ongoing Clinical Trials Overview
5.21 Lipocoat BV Company Overview
5.21.1 Lipocoat BV Pipeline Products & Ongoing Clinical Trials Overview
5.22 Lynthera Corp Company Overview
5.22.1 Lynthera Corp Pipeline Products & Ongoing Clinical Trials Overview
5.23 Massachusetts Eye and Ear Infirmary Company Overview
5.23.1 Massachusetts Eye and Ear Infirmary Pipeline Products & Ongoing Clinical Trials Overview
5.24 McGowan Institute for Regenerative Medicine Company Overview
5.24.1 McGowan Institute for Regenerative Medicine Pipeline Products & Ongoing Clinical Trials Overview
5.25 Mojo Vision Inc Company Overview
5.25.1 Mojo Vision Inc Pipeline Products & Ongoing Clinical Trials Overview
5.26 tiol University of Singapore Company Overview
5.26.1 tiol University of Singapore Pipeline Products & Ongoing Clinical Trials Overview
5.27 Novartis AG Company Overview
5.27.1 Novartis AG Pipeline Products & Ongoing Clinical Trials Overview
5.28 Ocular Dymics, LLC Company Overview
5.28.1 Ocular Dymics, LLC Pipeline Products & Ongoing Clinical Trials Overview
5.29 OcuMedic Inc Company Overview
5.29.1 OcuMedic Inc Pipeline Products & Ongoing Clinical Trials Overview
5.30 Ocutec Ltd Company Overview
5.30.1 Ocutec Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.31 RetMap Inc Company Overview
5.31.1 RetMap Inc Pipeline Products & Ongoing Clinical Trials Overview
5.32 Shamir Optical Industry Ltd Company Overview
5.32.1 Shamir Optical Industry Ltd Pipeline Products & Ongoing Clinical Trials Overview
5.33 SightGlass Vision Inc Company Overview
5.33.1 SightGlass Vision Inc Pipeline Products & Ongoing Clinical Trials Overview
5.34 Stanford University Company Overview
5.34.1 Stanford University Pipeline Products & Ongoing Clinical Trials Overview
5.35 TECLens LLC Company Overview
5.35.1 TECLens LLC Pipeline Products & Ongoing Clinical Trials Overview
5.36 The University of New South Wales press Limited Company Overview
5.36.1 The University of New South Wales press Limited Pipeline Products & Ongoing Clinical Trials Overview
5.37 University of California San Diego Company Overview
5.37.1 University of California San Diego Pipeline Products & Ongoing Clinical Trials Overview
5.38 University of Florida Company Overview
5.38.1 University of Florida Pipeline Products & Ongoing Clinical Trials Overview
5.39 University of New Hampshire Company Overview
5.39.1 University of New Hampshire Pipeline Products & Ongoing Clinical Trials Overview
5.40 University of Valencia Company Overview
5.40.1 University of Valencia Pipeline Products & Ongoing Clinical Trials Overview
5.41 University of Washington Company Overview
5.41.1 University of Washington Pipeline Products & Ongoing Clinical Trials Overview
5.42 Verily Life Sciences Company Overview
5.42.1 Verily Life Sciences Pipeline Products & Ongoing Clinical Trials Overview
5.43 Visioneering Technologies Inc Company Overview
5.43.1 Visioneering Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
5.44 VISTAKON Pharmaceuticals LLC Company Overview
5.44.1 VISTAKON Pharmaceuticals LLC Pipeline Products & Ongoing Clinical Trials Overview
5.45 Yolia Health Company Overview
5.45.1 Yolia Health Pipeline Products & Ongoing Clinical Trials Overview

6 Contact Lenses- Recent Developments
6.1 Nov 12, 2020: Bausch + Lomb reports nearly 27 million units of contact lens materials recycled through one by one recycling program
6.2 Oct 01, 2020: Essilor and Quisitive employ rapid application development to adapt to new operatiol norms
6.3 Sep 10, 2020: CooperCompanies and Divisions med one of Fortune’s Best Large Workplaces in Manufacturing and Production
6.4 Sep 07, 2020: Visioneering sees continued recovery
6.5 Sep 04, 2020: EssilorLuxottica : Update on legal proceedings to obtain information from GrandVision
6.6 Sep 01, 2020: Novartis announces ambitious ESG targets to increase access to medicines and achieve full carbon neutrality
6.7 Aug 18, 2020: Johnson & Johnson Vision announces new ACUVUE services and resources to enhance contact lens safety, comfort, and accessibility as part of contact lens health week
6.8 Jun 30, 2020: Menicon: A business tie-up agreement concluded with Chi’s Wenzhou Medical University
6.9 Jun 25, 2020: SEC charges Novartis with FCPA violations
6.10 Apr 24, 2020: Menicon announces completion of floor space expansion at its Kakamigahara Plant
6.11 Apr 20, 2020: EssilorLuxottica to prepare for recovery by preserving cash and supporting employees
6.12 Apr 13, 2020: New research reassures & advises contact lens wearers during COVID-19 pandemic; offers clear facts and hygiene advice
6.13 Apr 07, 2020: Alcon provides update on covid-19
6.14 Mar 13, 2020: Bausch Health to reduce debt by approximately $100 million using cash generated from operations
6.15 Mar 06, 2020: Pentax Medical dotes USD430,000 worth of medical devices to fight novel coro virus (2019-ncov)
6.16 Mar 04, 2020: High-Tech contact lenses correct color blindness
6.17 Mar 02, 2020: Alcon showcases contact lens, eye allergy and dry eye innovations as title sponsor of SECO2020
6.18 Feb 07, 2020: CooperCompanies appoints Mark Drury as new vice president, general counsel and corporate secretary and announces Randal L. Golden to retire
6.19 Feb 06, 2020: Mature presbyopes clinical research update presented at Global Specialty Lens Symposium (GSLS)
6.20 Feb 04, 2020: Visioneering Technologies achieves first sale in Singapore as Asian expansion accelerates
6.21 Jan 29, 2020: Novartis delivered strong sales growth, margin expansion and breakthrough innovation launching five NMEs in 2019
6.22 Jan 27, 2020: Bausch + Lomb and TerraCycle partner to launch Cada’s first and only contact lens recycling program
6.23 Jan 22, 2020: Novartis establishes its new legal entity in Vietm
6.24 Jan 16, 2020: Mojo Vision developing first true smart contact lens
6.25 Jan 16, 2020: Mojo Vision working with FDA, nonprofit organization to assist people with low vision
6.26 Jan 06, 2020: Bausch + Lomb launches expanded parameters for Biotrue ONEday for Astigmatism Daily Disposable Contact Lenses
6.27 Dec 16, 2019: Bausch Health Resolves ""Stock Drop"" Litigation initially filed in October 2015
6.28 Dec 06, 2019: FDA approves Myopia-slowing contact lens for children
6.29 Dec 05, 2019: Novartis expects to sustain long-term growth with a robust pipeline of 25+ potential blockbusters highlighted at R&D Day
6.30 Dec 05, 2019: CooperCompanies announces fourth quarter and full year 2019 results

7 Appendix
7.1 Methodology
7.2 About GlobalData
7.3 Contact Us
7.4 Disclaimer